Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer

NCT01658462 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Docetaxel
DRUG: Nintedanib
DRUG: Docetaxel: increase of the dose

Sponsor

Centre Oscar Lambret

Collaborators

[object Object]